Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones

Fineline Cube Aug 26, 2026
Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug PIC

GSK’s Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027

Fineline Cube Aug 26, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Deals

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal

Fineline Cube Feb 8, 2025

Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out...

Company Deals

Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets

Fineline Cube Feb 7, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s...

Company

Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches

Fineline Cube Feb 7, 2025

China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD...

Company

Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products

Fineline Cube Feb 7, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...

Company Drug

CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA

Fineline Cube Feb 7, 2025

China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration...

Company Drug

Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS

Fineline Cube Feb 7, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...

Company Drug

Hotgen Biotech Gains NMPA Approval for AA001 Clinical Trials in Alzheimer’s Disease

Fineline Cube Feb 7, 2025

China’s Hotgen Biotech Co., Ltd (SHA: 688068) announced that it has received clinical trial approval...

Company Drug

Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL

Fineline Cube Feb 7, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of...

Company Drug

Chipscreen Biosciences Gains NMPA Approval for Epidaza Phase III Study

Fineline Cube Feb 7, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that it has received approval from...

Company Drug

Alphamab and CSPC Gain NMPA Approval for JSKN003 Phase III Trial in HER2-Positive Breast Cancer

Fineline Cube Feb 7, 2025

Chinese partners Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that...

Company Drug

Gene Cradle’s GC310 Receives Tacit Approval from NMPA for Wilson’s Disease

Fineline Cube Feb 7, 2025

Beijing-based gene therapy specialist Gene Cradle announced that it has received tacit clinical approval from...

Company Drug

Hanx Biopharmaceuticals Gains NMPA Approval for HX044 Clinical Trials

Fineline Cube Feb 7, 2025

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clinical trial approval from...

Company Drug

Likang Life Sciences Gains FDA Approval for LK101 Clinical Trials

Fineline Cube Feb 7, 2025

Beijing-based cell therapy developer Likang Life Sciences announced that it has received approval from the...

Company Deals

CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition

Fineline Cube Feb 7, 2025

China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, has received approval from the State-owned...

Company Drug

EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment

Fineline Cube Feb 7, 2025

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Akeso Completes Enrollment for Global Phase III Trial of Ivonescimab in Lung Cancer

Fineline Cube Feb 7, 2025

China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the global...

Company Drug

Bayer Files for EMA Approval of Kerendia for Heart Failure

Fineline Cube Feb 7, 2025

Bayer AG (FRA: BAYN) announced that it has made another market filing with the European...

Company

Boston Scientific Posts Strong Q4 and Full-Year 2024 Results

Fineline Cube Feb 7, 2025

Boston Scientific Corporation (NYSE: BSX) released its Q4 and full-year 2024 financial report, showing robust...

Company Deals

Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange

Fineline Cube Feb 7, 2025

Suzhou-based Vigonvita Life Sciences Co., Ltd. has submitted an initial public offering (IPO) filing to...

Policy / Regulatory

NHSA Regulates DRG/DIP Payment Methods Under ‘1+3+N’ System

Fineline Cube Feb 7, 2025

The National Healthcare Security Administration (NHSA) has released a set of regulations aimed at improving...

Posts pagination

1 … 263 264 265 … 712

Recent updates

  • Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones
  • GSK’s Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027
  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones

Company Drug PIC

GSK’s Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.